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in all 60 institutions enrolled. Patients with polytrauma were not
included into the study. The effects of prognostic factors were
analysed by uni- and multivariate logistic regression (p″T0.05)
in three groups: 1) all fracture-related treatments; 2) non-
prosthetic; and 3) prosthetic treatments. RESULTS: Out of 413
patients, 17.92% required further fracture-related treatment. In
7.75% non-prosthetic, and in 10.17% prosthetic treatment was
performed. We demonstrated the odds ratios by multivariate
regression analysis according to risk factors [95% conﬁdence
interval, CI] are also given. Fracture displacement ORf2.243,
CI:[1.036–4.858] weekend surgery ORf2.347, CI:[1.049–5.248],
infections ORf3.681, CI:[1.172–11.55], central nervous system-
related co-morbidities ORf3.639, CI:[1.421–9.318] and the
county hospital level of management ORf2.356, CI:[0.997–
5.568] were associated with signiﬁcantly increased risk for
further surgery. CONCLUSION: To reduce the inﬂuence of risk
factors, standardization of the substantive traumatologic and
orthopedic professional guidelines, as well as the introduction
of common orthopedic-trauma patient care (British model) are
suggested. To achieve high-quality standardized patient manage-
ment, personal and material conditions are required to be acces-
sible every day of the week. In the presence of co-morbidities,
reduction of their harmful effects should be a major consider-
ation by focusing on the patient both in the peri- and postopera-
tive periods.
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OBJECTIVES: The aim of the present study was to investigate
the relationship between the delay of deﬁnitive surgical treat-
ment and mortality rates occurring within 30 days post-injury
in patients aged 60 or older with femoral neck fracture.
METHODS: Data were obtained from the database of the
National Health Insurance Fund and from the questionnaire
survey carried out by the institutions providing the treatment.
Logistic regression analysis was performed to analyse the cor-
relation between mortality risks within 30 days and delayed
surgery in patients operated at 12–24 h, 24–48 h or after 48 h
post-injury in comparison with mortality risks associated with
early (within 12 h) treatment. RESULTS: The number of
patients meeting the case deﬁnition criteria was 3777 with the
average age of 77.97 years. Mortality rates in four groups were
7.7%, 10.5%, 10.5% and 9.4%, respectively. According to
multiple regression analysis, all three groups (12–24 h, 24–48 h
and the over 48 h) showed a trend to increased mortality risks
but this was not statistically signiﬁcant (OR12–24 h = 1.301
CI12–24 h: 0.945–1.791, p = 0.106; OR24–48 h = 1.384 CI24–
48 h: 0.932–2.056, p = 0.108; OR48 h <= .246 CI48 h <:
0.950–1.635, p = 0.113). Sex, age and accompanying diseases
signiﬁcantly inﬂuenced early mortality, while early post-
operative complications did not have a signiﬁcant impact on the
mortality risks. CONCLUSION: The results of the present
study indicate the importance of early surgery in the treatment
of femoral neck fractures in order to decrease early mortality
associated with the disease in the elderly populations. Our
results highlight the importance of further evaluating the
reasons behind the delay in the surgical treatment (problems
during treatment, difﬁculties in surgical access, co-morbidity
etc.), especially in cases when surgery is performed with a 24 h
or longer post-injury delay in order to determine factors that
inﬂuence the prognostic signiﬁcance of surgical delay in the case
of different patient groups.
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OBJECTIVES: With at least 150,000 osteoporotic fractures in
France, annual cost for osteoporosis consequences was estimated
to about €600 millions. Poor diagnosis rate led French authori-
ties to decide reimbursement of bone mineral densitometry
(BMD) for osteoporosis high risk population in July 2006 (i.e.
postmenopausal women with at least one risk factor as deﬁned
by the National Union of the Health Insurance Services). Our
study was aimed to estimate the prevalence of osteoporosis risk
factors so as to assess the economic impact of this case-ﬁnding
strategy. METHODS: This cross-sectional epidemiological
survey was carried out within a representative population of
women aged 45 years and over constituted using a stratiﬁed
random sampling method (age, sex, socio-professional group,
and employment status). Face-to-face home interviews deter-
mined eligibility of women for BMD-screening and whether they
had underwent a BMD and received a diagnosis of osteoporosis.
Direct costs were assessed from the perspective of the health care
providers (i.e. BMD and physician consultation: 39.96€ and
18.60€ respectively). RESULTS: In our sample, 79.6% (2081) of
women were menopaused. 51.8% of them were eligible for
BMD-screening and 11.6%were already diagnosed by BMD with
osteoporosis. Among the diagnosed women, a third (31.0%)
didn’t have any risk factors and would not be eligible for the
screening. Based on these results, number of French eligible
women for BMD-screening would be about 5.8 millions associ-
ated with a total cost of €342 millions. Women diagnosed by
BMD were 1.3 million and could also achieve 2.3 millions rep-
resenting a cost per patient screened of 165€. CONCLUSION:
According to this study, the French case-ﬁnding strategy for
postmenopausal osteoporosis would cost €342 millions and
would lead to treat an additional one million patients.
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OBJECTIVES: Medication compliance is a signiﬁcant factor con-
tributing to the clinical- and cost-effectiveness of therapy. This
study aimed to investigate the evidence on the overall cost of
non-compliance with medication, taking osteoporosis therapy as
an example. METHODS: The speciﬁc question addressed was
“What are the direct medical health care costs of non-compliance
and non-persistence in osteoporosis”. A Literature review was
conducted to search for publications presenting work under the
broad terms “costs”, “compliance/persistence” and “osteoporo-
sis”. The databases searched were Medline, EMBASE, and the
Cochrane Library. The listings were then appraised to identify
those papers relevant to the study question and for inclusion in
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the evidence base. This evidence base was then investigated, in
order to assess ﬁndings to answer the study question. RESULTS:
In total, 52 papers were listed; four were relevant for inclusion.
two of these articles were retrospective cohort studies and two
were based on budget-impact models. Costs were presented as
medical charges; medication possession ratio (MPR) and/or per-
sistence rates were measures of non-compliance; osteoporosis
medications included bisphosphonates and HRT. US Medical
charges were 35% higher in non-compliers compared with
compliers and total monthly charges were 76% higher. Based
on modelling, persistence levels with bisphosphonates of <50%
at 12 months results in almost 20,000 excess fractures over a
10 year period and 22 M per annum fracture-related costs to
the UK NHS. CONCLUSION: The evidence base in this area is
limited. However, it indicates that medication non-compliance
and failure to persist has substantial ﬁnancial consequences
within the ﬁeld of osteoporosis management. This conclusion is
consistent with the evidence available from both observation
studies and modelling analyses in the US and UK health care
systems. Further work is warranted to review other disease
areas, and to further synthesise the data to provide an
estimated aggregate of the international cost of medication
non-compliance.
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OBJECTIVES: To assess the cost-effectiveness of an ongoing
osteoporosis screening campaign in Belgian women aged from
50 to 69 years. METHODS: A cost-effectiveness analysis was
performed using a decision tree analysis and a microsimulation
Markov model. We compared the screening campaign versus no
intervention. Screening campaign consisted of quantitative
ultrasound screening by mobile units. For all individuals having
a positive result, three possibilities are observed: no follow-up,
direct treatment or screening with DXA (dual energy X-ray
absorptiometry). Most of the individuals having a positive
DXA result received Alendronate therapy. Sensitivity analyses
and simulations were based on model parameters (discount
rates, fracture costs, fracture risks, fracture disutility, mortality
excess and treatment speciﬁcities), characteristics of screening
campaign (screening efﬁcacy, prevalence of osteoporosis and
screening cost), number of clinical risk factors and persistence
level. RESULTS: In the base case (with 100% persistence), the
cost per QALY gained for the screening strategy was €44,927.
Sensitivity analyses showed that this value was affected by per-
sistence level (€81,921 for realistic persistence). The efﬁciency
greatly improved if we only screen individuals with one clinical
risk factor (€23,265) or more (from €15,377 for two clinical
risk factors to cost-saving for four clinical risk factors). We also
showed that pre-screening using quantitative ultrasound was
more efﬁcient than universal DXA screening if the cost of quan-
titative ultrasound was less than €14.8 per patient screened.
CONCLUSION: The base case result was near to threshold
value of €45,000 per QALY gained. Consequently, it was dif-
ﬁcult to interpret the results and to qualify the campaign efﬁ-
ciency. Our recommendations to improve it are to target
screening on individuals with one or more clinical risk factors,
to generalize DXA for all individuals having a positive quanti-
tative ultrasound result, to treat all individuals having a posi-
tive DXA result and to improve compliance and adherence to
therapy.
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OBJECTIVES: To compare effectiveness, medical costs and cost-
effectiveness of zoledronic acid, one single yearly infusion, versus
usual care in post-menopausal osteoporosis in France, taking
into account compliance proﬁles. METHODS: Twelve simula-
tion based models were built to investigate 3 types of fractures:
vertebral (VF), non-vertebral (NVF) and hip (HF), comparing 2
groups: zoledronic acid and usual care. Two effectiveness
assumptions have been tested to handle the issue of clinical trial
population heterogeneity: 1) speciﬁc agent effectiveness values,
and 2) same standard effectiveness range of values for all active
agents. Direct medical costs include drug costs, medical visits,
monitoring and fracture medical management. Compliance has
been integrated into the model with the assumption that non-
compliant patients have the placebo effectiveness range of values.
Conservative compliance range of rates for active agents has been
expressed in accordance with the literature and expert opinion,
from 40% to 60% for oral drugs and from 50% to 100% for
Zoledronic acid single yearly infusion. A full probabilistic sensi-
tivity analysis has been carried out to generate costs, effectiveness
and cost-effectiveness over 3 years, with conﬁdence intervals.
Statistical tests were performed to calculate potential signiﬁcant
differences. RESULTS: Using the second assumption (2), the
zoledronic acid strategy leads to less vertebral, non-vertebral
and hip fractures than usual care: (88.0% vs. 85.7%,
89.4% vs. 88.2% and 97.2% vs. 95.4%) respectively, (p <
0.001). Zoledronic acid generates lower total medical costs
versus usual care in all types of fracture (p < 0.001): 944€ vs.
995€ (VF), 1164€ vs. 1245€ (NVF) and 1156€ vs. 1261€ (HF).
CONCLUSION: Zoledronic acid is the dominant strategy,
regardless of fracture type or effectiveness assumptions. A simu-
lation modeling approach seems appropriate to investigate
various effectiveness values from heterogeneous clinical trials.
Isolating the compliance effect allows us to conﬁrm the added
value of a once yearly infusion of zoledronic acid 5 mg.
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OBJECTIVES: To evaluate the cost effectiveness of zoledronic
acid 5 mg once yearly compared to the leading branded com-
pounds in the UK, i.e. Fosamax once weekly, Actonel once
weekly, Bonviva once monthly, and Protelos once daily in
patients with postmenopausal osteoporosis. METHODS: The
cost effectiveness model applied tracks the model NICE used in
their appraisal document for the cost effectiveness of treatments
of osteoporosis in postmenopausal women at increased risk of
fracture. Lifetime costs and quality adjusted life years (QALYs)
were calculated assuming ﬁve years of treatment. Relative risks
of fracture protection were obtained from the HORIZON-PFT
trial for zoledronic acid 5 mg, meta-analyses from NICE reviews
Abstracts A395
